Home-based peroneal electrical transcutaneous NeuroModulation (peroneal eTNM®) in Parkinson's disease as "add-on" treatment - Results of a pilot study.

ABSTRACT:

Introduction

Currently, there is no causal cure for Parkinson's disease (PD), and medications and other therapeutic procedures only allow for the reduction of symptoms. Noninvasive neuromodulation is among the potentially promising treatments for PD patients. The present pilot study aimed to evaluate the safety and efficacy of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) in the treatment of PD symptoms with a particular emphasis on disease-related quality of life.

Methods

Twelve patients with clinically established Parkinsońs disease (8 males; mean age 59.5 ± 11.6 years) were enrolled. In addition to state-of-the-art background pharmacotherapy for PD, patients were treated with peroneal eTNM® daily for 30 min for 6 weeks followed by 6 weeks of follow-u

SUBMITTER: Bartova P 

PROVIDER: S-EPMC12017861 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature